Results 81 to 90 of about 145,187 (366)

Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice

FEBS Open Bio, EarlyView.
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda, Satoru Sugimoto, Chiharu Cho, Madoka Konishi, Nozomi Inoue, Satoshi Miyagaki, Yasuhiro Kawabe, Takuro Okamura, Masahide Hamaguchi, Hisakazu Nakajima, Michiaki Fukui, Masakazu Shinohara, Tomoko Iehara   +12 more
wiley   +1 more source

CD11b+CD43hiLy6Clo splenocyte‐derived macrophages exacerbate liver fibrosis via spleen–liver axis

Hepatology, EarlyView., 2022
A population of splenic monocytes migrate into the liver and shift to macrophages, which account for the exacerbation of liver fibrosis. Abstract Background and Aims Monocyte‐derived macrophages (MoMFs), a dominant population of hepatic macrophages under inflammation, play a crucial role in liver fibrosis progression.
Shaoying Zhang, Dan Wan, Mengchen Zhu, Guihu Wang, Xurui Zhang, Na Huang, Jian Zhang, Chongyu Zhang, Qi Shang, Chen Zhang, Xi Liu, Fanfan Liang, Chunyan Zhang, Guangyao Kong, Jing Geng, Libo Yao, Shemin Lu, Yongyan Chen, Zongfang Li   +18 more
wiley   +1 more source

Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)

Liver international (Print), 2021
NAFLD/NASH is a sex‐dimorphic disease, with a general higher prevalence in men. Women are at reduced risk of NAFLD compared to men in fertile age, whereas after menopause women have a comparable prevalence of NAFLD as men.
P. Burra, D. Bizzaro, Anna Gonta, S. Shalaby, M. Gambato, M. Morelli, S. Trapani, A. Floreani, F. Marra, M. Brunetto, G. Taliani, E. Villa   +11 more
semanticscholar   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

Arthritis Care &Research, EarlyView.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung, John P. Shelley, Gul Karakoc, John Still, Xiaodi Ruan, Jonathan Mosley, C. Michael Stein, Vivian K. Kawai   +7 more
wiley   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Protective Properties of FOXO1 Inhibition in a Murine Model of Non-alcoholic Fatty Liver Disease Are Associated With Attenuation of ER Stress and Necroptosis

Frontiers in Physiology, 2020
AimThe pathogenesis of non-alcoholic fatty liver disease is currently unclear, however, lipid accumulation leading to endoplasmic reticulum stress appears to be pivotal in the process. At present, FOXO1 is known to be involved in NAFLD progression.
Hao-ran Ding, Hao-ran Ding, Hao-ran Ding, Zhen-ting Tang, Ning Tang, Zheng-yi Zhu, Han-yi Liu, Chen-yan Pan, An-yin Hu, Yun-zhen Lin, Peng Gou, Xian-wen Yuan, Jia-hui Cai, Chun-long Dong, Jing-lin Wang, Jing-lin Wang, Jing-lin Wang, Hao-zhen Ren, Hao-zhen Ren, Hao-zhen Ren   +19 more
doaj   +1 more source

Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study [PDF]

, 2016
Nonalcoholic fatty liver disease (NAFLD) includes steatosis and nonalcoholic steatohepatitis (NASH), which can be complicated by cirrhosis and hepatocellular carcinoma [1].
CARNOVALE, ANNA, FILARDI, TIZIANA, LENZI, Andrea, MARIANI, Paola, MORANO, Susanna, Nieddu, Luciano, PALLOTTA, Nadia, VINCOLI, GIUSEPPINA   +7 more
core   +1 more source

Alcoholic and non-alcoholic steatohepatitis [PDF]

Experimental and Molecular Pathology, 2014
This paper is based upon the “Charles Lieber Satellite Symposia” organized by Manuela G. Neuman at the Research Society on Alcoholism (RSA) Annual Meetings, 2013 and 2014. The present review includes pre-clinical, translational and clinical research that characterize alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH). In addition, a
Manuela G, Neuman, Samuel W, French, Barbara A, French, Helmut K, Seitz, Lawrence B, Cohen, Sebastian, Mueller, Natalia A, Osna, Kusum K, Kharbanda, Devanshi, Seth, Abraham, Bautista, Kyle J, Thompson, Iain H, McKillop, Irina A, Kirpich, Craig J, McClain, Ramon, Bataller, Radu M, Nanau, Mihai, Voiculescu, Mihai, Opris, Hong, Shen, Brittany, Tillman, Jun, Li, Hui, Liu, Paul G, Thomes, Murali, Ganesan, Steve, Malnick   +24 more
openaire   +2 more sources

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Frontiers in Endocrinology, 2020
The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation in the liver.
Erik J. Tillman, T. Rolph
semanticscholar   +1 more source

LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver

Advanced Materials, EarlyView.
The lipid droplet inhibitor (LDI), templated with large‐pore mesoporous silica and functionalized with PKCα C1A and lipase, targets lipid degradation in fatty liver. The LDI maintains stable association with lipid droplets, thereby suppressing their formation and expansion.
Seunghee Kim, Yeojin Kim, Sanjita Paudel, In Young Kang, Suyeon Kim, Jeesoo Kim, Sunmi Park, Seung‐Hoi Koo, Hyun Sung Kim, Dae Won Jun, Jinyoung Park, Hyunbeom Lee, Joonseok Lee   +12 more
wiley   +1 more source